Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations. 

The settlements include $24m for alleged kickbacks paid by the subsidiary formerly known as Respironics, as well as $4.2m for selling devices to the US military that weren’t certified for use in the air.

Moderna is seeking financial compensation for Comirnaty in its patent infringement suit, but it seems especially keen to assert IP rights over what could become an even more valuable platform technology.

A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.